|
Characteristic
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
HR
|
95% CI
|
P value
|
HR
|
95% CI
|
P value
|
|---|
|
Age
|
|
≤ 50
|
1.000
| | |
1.000
| | |
|
51–64
|
0.783
|
0.515–1.193
|
0.255
|
0.899
|
0.585–1.382
|
0.628
|
|
≥ 65
|
1.929
|
1.327–2.805
|
0.001
|
2.494
|
1.657–3.752
|
< 0.001
|
|
Race
|
|
White
|
1.000
| | |
–
|
–
|
–
|
|
African American
|
1.001
|
0.667–1.503
|
0.995
|
–
|
–
|
–
|
|
Other
|
0.591
|
0.277–1.257
|
0.172
|
–
|
–
|
–
|
|
Sex
|
|
Female
|
1.000
| | |
–
|
–
|
–
|
|
Male
|
1.130
|
0.465–2.740
|
0.787
|
–
|
–
|
–
|
|
Charlson–Deyo comorbidity score
|
|
0
|
1.000
| | |
1.000
| | |
|
1
|
1.871
|
1.311–2.671
|
0.001
|
1.513
|
1.049–2.183
|
0.027
|
|
≥ 2
|
3.349
|
1.898–5.910
|
< 0.001
|
2.200
|
1.217–3.978
|
0.009
|
|
Clinical T stage
|
|
1
|
1.000
| | |
1.000
| | |
|
2
|
2.052
|
1.507–2.794
|
< 0.001
|
1.888
|
1.340–2.660
|
< 0.001
|
|
3
|
2.345
|
1.504–3.656
|
< 0.001
|
2.230
|
1.314–3.784
|
0.003
|
|
4
|
3.649
|
2.222–5.993
|
< 0.001
|
2.851
|
1.602–5.073
|
< 0.001
|
|
Clinical N stage
|
|
0
|
1.000
| | |
1.000
| | |
|
1
|
1.546
|
1.122–2.130
|
0.008
|
1.194
|
0.771–1.850
|
0.426
|
|
2
|
3.832
|
2.390–6.147
|
< 0.001
|
2.009
|
1.099–3.676
|
0.024
|
|
3
|
1.825
|
0.852–3.908
|
0.122
|
0.925
|
0.292–2.184
|
0.859
|
|
Surgery
|
|
Lumpectomy
|
1.000
| | |
1.000
| | |
|
Mastectomy
|
1.373
|
1.040–1.812
|
0.025
|
1.027
|
0.751–1.404
|
0.869
|
|
Radiotherapy
|
|
Yes
|
1.000
| | |
1.000
| | |
|
No
|
1.755
|
1.336–2.307
|
< 0.001
|
2.344
|
1.711–3.210
|
< 0.001
|
|
Histologic grade
|
|
Well differentiated
|
1.000
| | |
–
|
–
|
–
|
|
Moderately differentiated
|
0.981
|
0.558–1.723
|
0.946
|
–
|
–
|
–
|
|
Poorly differentiated/undifferentiated
|
1.457
|
0.831–2.552
|
0.189
|
–
|
–
|
–
|
|
Not reported
|
0.721
|
0.291–1.788
|
0.481
|
–
|
–
|
–
|
|
ER status
|
|
Positive
|
1.000
| | |
1.000
| | |
|
Negative
|
2.245
|
1.629–3.113
|
< 0.001
|
2.804
|
1.827–4.305
|
< 0.001
|
|
Unknown
|
0.704
|
0.260–1.906
|
0.490
|
0.585
|
0.211–1.626
|
0.304
|
|
PR status
|
|
Positive
|
1.000
| | |
1.000
| | |
|
Negative
|
1.6501
|
1.223–2.227
|
0.001
|
1.586
|
1.166–2.156
|
0.003
|
|
Unknown
|
0.731
|
0.298–1.788
|
0.492
|
0.825
|
0.335–2.045
|
0.677
|
|
HER2 status
|
|
Positive
|
1.000
| | |
–
|
–
|
–
|
|
Negative
|
1.021
|
0.604–1.728
|
0.937
|
–
|
–
|
–
|
|
Unknown
|
0.857
|
0.503–1.460
|
0.570
|
–
|
–
|
–
|
|
Chemotherapy
|
|
Yes
|
1.000
| | |
–
|
–
|
–
|
|
No
|
0.914
|
0.679–1.230
|
0.552
|
–
|
–
|
–
|
|
Not reported
|
1.314
|
0.874–1.977
|
0.189
|
–
|
–
|
–
|
|
Hormonal therapy
|
|
Yes
|
1.000
| | |
1.000
| | |
|
No
|
1.526
|
1.134–2.054
|
0.005
|
0.789
|
0.538–1.158
|
0.227
|
|
Not reported
|
1.296
|
0.745–0.254
|
0.358
|
1.013
|
0.567–1.810
|
0.965
|
|
Lymph nodes involved
|
|
0
|
1.000
| | |
1.000
| | |
|
1–3
|
0.971
|
0.656–1.438
|
0.883
|
1.087
|
0.700–1.687
|
0.711
|
|
4 or more
|
2.438
|
1.750–3.398
|
< 0.001
|
2.292
|
1.413–3.719
|
0.001
|
|
Unknown
|
1.823
|
1.174–0.828
|
0.007
|
1.507
|
0.962–2.361
|
0.073
|
- OS overall survival, HR hazard ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
